Gesynta Pharma

Stockholm, Sweden

Drug candidates with a unique mechanism of action, aiming to reduce inflammation and pain. Vipoglanstat to enter phase II for endometriosis.

$27.3M raised

Jan 2025

Series B

Biopharma Health Care Pharmaceutical

Top Investors

InnovestorAmboy Street VenturesHadean VenturesIndustrifondenStephen Industries

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Gesynta Pharma

How much funding has Gesynta Pharma raised?

Gesynta Pharma has raised $27.3M in total funding. The most recent round was Series B. The last funding was announced in January 2025.

Who are Gesynta Pharma's investors?

Gesynta Pharma's investors include Innovestor, Amboy Street Ventures, Hadean Ventures, Industrifonden, Stephen Industries.

Where is Gesynta Pharma headquartered?

Gesynta Pharma is headquartered in Stockholm, Sweden.

What does Gesynta Pharma do?

Drug candidates with a unique mechanism of action, aiming to reduce inflammation and pain. Vipoglanstat to enter phase II for endometriosis.

What stage is Gesynta Pharma at?

Gesynta Pharma is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 20, 2025.

MLA

"Gesynta Pharma — Funding & Investors." VCBacked, January 20, 2025, https://www.vcbacked.co/company/gesynta-pharma. Accessed June 4, 2026.

APA

VCBacked. (2025). Gesynta Pharma — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/gesynta-pharma

Wikipedia (cite web)

{{cite web |title=Gesynta Pharma — Funding & Investors |url=https://www.vcbacked.co/company/gesynta-pharma |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 20, 2025.

Similar Companies in Biopharma